School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, People's Republic of China.
Department of Science and Education, Hong Hui Hospital, Xi'an Jiaotong University, Xi'an, People's Republic of China.
Phytother Res. 2024 Jan;38(1):131-146. doi: 10.1002/ptr.8029. Epub 2023 Oct 11.
Neuroblastoma and glioblastoma are primary malignant tumors of the nervous system, with frequent relapse and limited clinical therapeutic drugs. The failure of their treatment is due to the tumor cells exhibiting cancer stem-like cells (CSLCs) properties. Octamer binding transcription factor 4 (Oct4) is involved in mediating CSLCs, our previous work found that Oct4-driven reprogramming of astrocytes into induced neural stem cells was potentiated with continuous sonic hedgehog (Shh) stimulation. In this study, we aimed to study the importance of Oct4 and Shh combination in the stemness properties induction of neuroblastoma and glioblastoma cells, and evaluate the anti-stemness effect of dauricine (DAU), a natural product of bis-benzylisoquinoline alkaloid. The effect of Oct4 and Shh co-activation on cancer stemness was evaluated by tumor spheres formation model and flow cytometry analysis. Then the effects of DAU on SH-SY5Y and T98-G cells were assessed by the MTT, colony formation, and tumor spheres formation model. DAU acts on Oct4 were verified using the Western blotting, MTT, and so on. Mechanistic studies were explored by siRNA transfection assay, Western blotting, and flow cytometry analysis. We identified that Shh effectively improved Oct4-mediated generation of stemness in SH-SY5Y and T98-G cells, and Oct4 and Shh co-activation promoted cell growth, the resistance of apoptosis. In addition, DAU, a natural product, was found to be able to attenuate Oct4/Shh co-activated stemness and induce cell cycle arrest and apoptosis via blocking AKT/β-catenin signaling in neuroblastoma and glioblastoma, which contributed to the neuroblastoma and glioblastoma cells growth inhibition by DAU. In summary, our results indicated that the treatment of DAU may be served as a potential therapeutic method in neuroblastoma and glioblastoma.
神经母细胞瘤和胶质母细胞瘤是神经系统的原发性恶性肿瘤,常复发且临床治疗药物有限。其治疗失败是由于肿瘤细胞表现出癌症干细胞样细胞(CSLCs)的特性。八聚体结合转录因子 4(Oct4)参与介导 CSLCs,我们之前的工作发现,Oct4 驱动的星形胶质细胞重编程为诱导性神经干细胞在持续的 Sonic Hedgehog(Shh)刺激下得到增强。在这项研究中,我们旨在研究 Oct4 和 Shh 联合在神经母细胞瘤和胶质母细胞瘤细胞干性诱导中的重要性,并评估天然产物 dauricine(DAU)对 stemness 的抗作用,一种双苄基异喹啉生物碱。通过肿瘤球体形成模型和流式细胞术分析评估 Oct4 和 Shh 共同激活对癌症干性的影响。然后通过 MTT、集落形成和肿瘤球体形成模型评估 DAU 对 SH-SY5Y 和 T98-G 细胞的作用。使用 Western blot、MTT 等方法验证 DAU 对 Oct4 的作用。通过 siRNA 转染试验、Western blot 和流式细胞术分析探索了机制研究。我们确定 Shh 有效地提高了 Oct4 在 SH-SY5Y 和 T98-G 细胞中介导的干性生成,并且 Oct4 和 Shh 的共同激活促进了细胞生长,抗细胞凋亡。此外,发现天然产物 DAU 能够通过阻断 AKT/β-catenin 信号通路减弱 Oct4/Shh 共同激活的干性,并诱导细胞周期停滞和凋亡,从而导致 DAU 抑制神经母细胞瘤和胶质母细胞瘤细胞的生长。总之,我们的结果表明,DAU 的治疗可能是神经母细胞瘤和胶质母细胞瘤的一种潜在治疗方法。